I don't understand this statement. While Eliquis start up was much slower than expected it is growing in share every week. Pradaxa and Xarelto are tough competitors and good drugs. I currently have a 35% share of new RXs. While I'm above average it is clear that Eliquis is getting a lot of business and it is with those prescribers who are reading and interpreting the data. Eliquis's data has stood the test of intense scrutiny and after just a year and a half is getting close to taking a third of the market.